

## Absence of Association between -1131T>C Polymorphism in the Apolipoprotein APOA5 Gene and Pediatric Metabolic Syndrome

Sayedeh Ghazaleh Fatemi, MSc<sup>1</sup>; Modjtaba Emadi-Baygi, PhD<sup>1,2</sup>; Parvaneh Nikpour\*, PhD<sup>3,4,5</sup>; Roya Kelishadi, MD<sup>5</sup>; Mahin Hashemipour, MD<sup>5</sup>

<sup>1</sup>Department of Genetics, School of Basic Sciences, <sup>2</sup>Research Institute of Biotechnology, School of Basic Sciences, Shahrekord University, Shahrekord, <sup>3</sup>Pediatric Inherited Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, <sup>4</sup>Department of Genetics and Molecular Biology, School of Medicine, <sup>5</sup>Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Received: Jun 24, 2013; Accepted: Jan 29, 2014; First Online Available: May 08, 2014

### Abstract

**Objective:** In the present study, we evaluated the association of rs662799 variant of the *APOA5* gene with Metabolic syndrome (MetS) in a sample of children and adolescents from Isfahan.

**Methods:** This case control study comprised 50 cases of MetS and 50 controls. Mismatched polymerase chain reaction–restriction fragment length polymorphism (mPCR-RFLP) was used to genotype -1131T>C polymorphism.

**Findings:** No significant association was documented for *APOA5* genotypes with the measured laboratory parameters for CC, CT, and TT genotypes in the two groups studied. By logistic regression using a dominant model, the odds ratio (95% confidence interval) for the MetS was 0.38 (0.139–1.0350 and 0.29 (0.08–1.071 for the unadjusted and adjusted models, respectively.

**Conclusion:** This study suggests that among studied children and adolescents, -1131T>C polymorphism in the *APOA5* gene may not be a major contributor to the MetS risk.

*Iranian Journal of Pediatrics, Volume 24 (Number 3), June 2014, Pages: 319-322*

**Key Words:** Apolipoprotein A5 Gene; Metabolic Syndrome; Children; Adolescents; Triglyceride; Cholesterol

### Introduction

Metabolic syndrome (MetS) is a prevalent complex disorder consisting of concurrent metabolic abnormalities<sup>[1]</sup>. The prevalence of the syndrome is 1-2% in Iranian children and adolescents, much higher than that reported for other ethnicities<sup>[2-4]</sup>. It markedly increases the risk of developing cardiovascular diseases and type 2 diabetes<sup>[5]</sup>. According to the ATPIII criteria, MetS can be diagnosed based on hypertension, central obesity,

insulin resistance and dyslipidemia. However, the most frequent components of the MetS in Iranian children and adolescents are low high-density lipoprotein cholesterol (HDL-C) and high triglycerides (TG)<sup>[2]</sup>.

Among the genetic variants associated with the development of MetS, there is a naturally occurring variant (-1131T>C) in the promoter region of apolipoprotein A5 gene (*APOA5*). The mature *APOA5* protein expresses exclusively in the liver and secretes into the plasma to modulate

\* Corresponding Author;

Address: Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

E-mail: pnkpour@med.mui.ac.ir

© 2014 by Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, All rights reserved.

TG metabolism<sup>[6]</sup>.

The -1131T>C (rs662799) variant of *APOA5* gene is associated with increased triglyceride levels and confers risk for metabolic syndrome in adult populations<sup>[7-13]</sup>. However, little is known about the *APOA5* variants in pediatric MetS. In the present study, we evaluated the association of rs662799 variant of the *APOA5* gene with MetS in Isfahanian children and adolescents.

## Subjects and Methods

A total of 50 cases of MetS and 50 controls were recruited to this study. Controls had normal weight and were healthy looking, without any clinical, laboratory or history records for MetS, diabetes or cardiovascular disorders. To diagnose the individuals with MetS, we used the modified ATPIII definition<sup>[2]</sup>. In brief, a MetS subject fulfilled at least three of the following components: waist circumference >75<sup>th</sup> percentile for age and gender in the studied population; fasting TG ≥100mg/dl; HDL-C <50 mg/dl (except in 15-19 year boys in whom the cut off was <45 mg/dl); systolic blood pressure/diastolic blood pressure >90<sup>th</sup> percentile recommended cut off points by the National Heart, Lung and Blood institute for gender, age and height<sup>[14]</sup>; fasting blood sugar (FBS) ≥100 mg/dl<sup>[2]</sup>. This study was approved by the Ethic Committee of Isfahan University. Informed consent was obtained from parents. The experimental design was approved by the Ethics Committee of Shahrekord University.

Blood specimens were collected in EDTA-treated tubes and were stored at -70°C for further analysis. Extraction of DNA from total blood was

performed using the Diatom DNA Prep 100 kit (Isogen Laboratory, Russia). mPCR-RFLP was used to genotype T>C polymorphism with primers described elsewhere<sup>[7]</sup>. The amplified fragment possessed an obligatory cleavage site for *TruI* restriction endonuclease to check if the digestion has occurred. Thermal conditions of the PCR cycles were as follow: initial denaturation at 95°C followed by 35 amplification cycles consisting of denaturation at 95°C for 40 sec; annealing at 61°C for 40 sec; extension at 72°C for 40 sec and a final extension at 72°C for 10 min. 10 µl of the PCR product was digested with 5 U of *TruI* enzyme. According to the digestion patterns, three genotypes were determined: TT genotype resulted in 21, 108 and 267 bp fragments, TC genotype created 21, 108, 267 and 288 bp products and CC genotype produced 108 and 288 bp fragments.

Statistical analyses were done with SPSS software (version 20.0). *P* values less than 0.05 were considered significant. A Chi-square statistic was calculated to compare the frequencies of genotypes and alleles. One way ANOVA was conducted to evaluate any differences between different groups, regarding the levels of biochemical factors and the distribution of different genotypes. Logistic regression analysis was performed to derive the odds ratios.

## Findings

The major relevant clinical and biochemical characteristics of the study participants are presented in Table 1. The main risk factors for MetS were significantly augmented in the MetS cases except for HDL-C (*P*<0.01).

**Table 1:** Clinical and biochemical data of the MetS and control subjects

Parameter	Cases (n=50)	Controls (n=50)	<i>P</i> value
Boys/Girls	22(44%)/28(56%)	25(50%)/25(50%)	0.5
Body mass index (kg/m <sup>2</sup> )	26.4 (0.45)	17.85 (0.94)	<0.001
Age (years)	12.18 (0.24)	13.48 (0.44)	0.01
Triglyceride (mg/dl)	109.64 (8.24)	78.44 (5.12)	0.002
Total Cholesterol (mg/dl)	165.12 (3.80)	151.48 (14.14)	0.02
High Density Lipoprotein-C (mg/dl)	43.08 (0.74)	50.44 (1.74)	<0.001
Low Density Lipoprotein -C (mg/dl)	95.66 (3.32)	79.32 (1.88)	<0.001
Fasting Blood Sugar (mg/dl)	102.56 (1.35)	91.24 (1.77)	<0.001

**Table 2:** Biochemical factor levels in MetS and control subjects according to the *APOA5* -1131T>C genotypes

Biochemical factors	Cases			Controls		
	TT (n=43)	TC+CC (n=7)	P. value	TT (n=35)	TC+CC (n=15)	P. value
TG (mg/dl)	111.93 (59.55)	95.57 (51.33)	0.2	77.37 (36.14)	80.93 (37.59)	0.4
TC (mg/dl)	164.05 (24.99)	171.71 (38.74)	0.2	152.51 (30.52)	149.07 (27.07)	0.3
HDL-C (mg/dl)	43.37 (4.99)	41.29 (5.67)	0.2	49.97 (13.39)	51.53 (9.97)	0.3
FBS (mg/dl)	102.30 (8.64)	104.14 (15.08)	0.3	91.60 (14.51)	90.40 (6.35)	0.4
LDL-C (mg/dl)	93.93 (21.41)	106.29 (33.93)	0.1	80.71 (12.56)	76.07 (14.80)	0.1

TG: Triglyceride; TC: Total cholesterol; HDL-C: High density lipoprotein-cholesterol; LDL-C: Low density lipoprotein-cholesterol; FBS: Fasting blood sugar

Table 2 shows the comparison of the laboratory parameters of the control and MetS subjects stratified based on rs662799 genotypes. The data demonstrated that there was no evidence of an association of *APOA5* genotypes with any of laboratory parameters. Genotype and allele frequencies are shown in Table 3. The data revealed that the frequency of C allele was greater in controls compared with that of the MetS. The odds ratio of the C allele in MetS versus control subjects in the unadjusted model was OR=0.38, 95%CI: 0.14-1.03,  $P=0.05$ . The Odds ratio adjusted for sex, age, HDL-C and TC was also calculated (OR=0.29, 95%CI: 0.08-1.07,  $P=0.06$ ) and no significant differences between adjusted and unadjusted models were found (Table 4).

## Discussion

We did not find an association between the -1131C polymorphism and elevated triglyceride levels. A number of studies have reported a significant association between triglyceride levels and the -1131T>C variant in MetS adults and obese children<sup>[7-10,15-18]</sup>. Our finding was in agreement with Mattei 's<sup>[19]</sup> results which showed

no association between TG levels and the -1131T>C. This inconsistency may be due to ethnicity influences<sup>[20]</sup>. Moreover, no association was found between the -1131T>C and MetS in our study. Significant correlation of -1131T>C *APOA5* variant with MetS in adults has been indicated in several<sup>[8-13]</sup> but not all previous studies<sup>[7,17-19]</sup>. The findings of the current study are consistent with a recent meta-analysis<sup>[21]</sup> which showed that C allele carriers of -1131T>C had overall a significantly higher risk of MetS. After performing subgroup analysis according to ethnicity, the association was only significant in Asians, but not in white populations.

## Conclusion

We showed that -1131T>C variant was neither associated with triglyceride levels nor MetS. Our results call for further studies to explore the effect of other *APOA5* SNPs and haplotypes in Iranian children and adolescents.

**Table 3:** Genotype and allele frequencies

Group		Cases (n=50)	Controls (n=50)
Allele frequencies	C	6 (12%)	9 (18%)
	T	44 (88%)	41 (82%)
Genotype frequencies	TT	43 (86%)	35 (70%)
	TC	2 (4%)	12 (24%)
	CC	5 (10%)	3 (6%)

**Table 4:** Binary logistic regression analysis of the association between carrying *APOA5* -1131C allele and the risk for MetS

Group		TT	TC+CC
Cases (n=50)		43 (86%)	7 (14%)
Controls (n=50)		35 (70%)	15 (30%)
Unadjusted model	Odds ratio	0.38	
	95% CI	0.14-1.03	
	P. value	0.05	
Adjusted model	Odds ratio	0.29	
	95%CI	0.08-1.07	
	P. value	0.06	

CI: Confidence Interval

## Acknowledgment

This study was supported in part by a research grant to MEB from the Research Institute of Biotechnology, Shahrekord University, Shahrekord, Iran.

## Authors' Contribution

S.G. Fatemi: Doing experiments, analysis of data, drafting the article.

M. Emadi-Baygi: Conception, designing the study, analysis and interpretation of data the article.

P. Nikpour: Conception, designing the study, analysis and interpretation of data and drafting and revising the article.

R. Kelishadi: Sample collection, designing the study, analysis and interpretation of data the article.

M. Hashemipour: Sample collection, analysis and interpretation of data the article.

All authors approved final version of the manuscript.

**Conflict of Interest:** None

## References

1. Roche HM, Phillips C, Gibney MJ. The metabolic syndrome: the crossroads of diet and genetics. *Proc Nutr Soc* 2005;64(3):371-7.
2. Kelishadi R, Ardalan G, Gheiratmand R, et al. Paediatric metabolic syndrome and associated anthropometric indices: the CASPIAN Study. *Acta Paediatr* 2006;95(12):1625-34.
3. Schwandt P, Kelishadi R, Haas GM. Ethnic disparities of the metabolic syndrome in population-based samples of German and Iranian adolescents. *Metab Syndr Relat Disord* 2010;8(2):189-92.
4. Schwandt P, Kelishadi R, Ribeiro RQ, et al. A three-country study on the components of the metabolic syndrome in youths: the BIG Study. *Int J Pediatr Obes* 2010;5(4):334-41.
5. Beilin L, Huang RC. Childhood obesity, hypertension, the metabolic syndrome and adult cardiovascular disease. *Clin Exp Pharmacol Physiol* 2008;35(4):409-11.
6. Tai ES, Orдовas JM. Clinical significance of apolipoprotein A5. *Curr Opin Lipidol* 2008;19(4):349-54.
7. Maasz A, Kisfali P, Horvatovich K, et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. *Pathol Oncol Res* 2007;13(3):243-7.
8. Song KH, Yu SG, Cha S, et al. Association of the Apolipoprotein A5 Gene -1131T>C Polymorphism with Serum Lipids in Korean Subjects: Impact of Sasang Constitution. *Evid Based Complement Alternat Med* 2012;2012(598394).
9. Hiramatsu M, Oguri M, Kato K, et al. Synergistic effects of genetic variants of APOA5 and BTN2A1 on dyslipidemia or metabolic syndrome. *Int J Mol Med* 2012;30(1):185-92.
10. Xu C, Bai R, Zhang D, et al. Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis. *PLoS One* 2013;8(2):e56216.
11. Komurcu-Bayrak E, Onat A, Poda M, et al. Gender-modulated impact of apolipoprotein A5 gene (APOA5) -1131T>C and c.56C>G polymorphisms on lipids, dyslipidemia and metabolic syndrome in Turkish adults. *Clin Chem Lab Med* 2008;46(6):778-84.
12. Hsu LA, Ko YL, Chang CJ, et al. Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan. *Clin Chem Lab Med* 2008;46(12):1714-9.
13. Yamada Y, Kato K, Hibino T, et al. Prediction of genetic risk for metabolic syndrome. *Atherosclerosis* 2007;191(2):298-304.
14. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. *Pediatrics*. 1996; 98(649-658).
15. Endo K, Yanagi H, Araki J, et al. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. *Hum Genet* 2002; 111(6):570-2.
16. Horvatovich K, Bokor S, Barath A, et al. Haplotype analysis of the apolipoprotein A5 gene in obese pediatric patients. *Int J Pediatr Obes* 2011;6(2-2): e318-25.
17. Grallert H, Sedlmeier EM, Huth C, et al. APOA5 variants and metabolic syndrome in Caucasians. *J Lipid Res* 2007;48(12):2614-21.
18. Kifali P, Mohas M, Maasz A, et al. Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. *Nutr Metab Cardiovasc Dis* 2009;20(7):505-11.
19. Mattei J, Demissie S, Tucker KL, et al. Apolipoprotein A5 polymorphisms interact with total dietary fat intake in association with markers of metabolic syndrome in Puerto Rican older adults. *J Nutr* 2009; 139(12):2301-8.
20. Dorfmeister B, Cooper JA, Stephens JW, et al. The effect of APOA5 and APOC3 variants on lipid parameters in European whites, Indian Asians and Afro-Caribbeans with type 2 diabetes. *Biochim Biophys Acta* 2007;1772(3):355-63.
21. Liu CF, Yang QF, Chen XL, Liu CY. Apolipoprotein a5 gene polymorphism and risk for metabolic syndrome: a meta-analysis. *Genet Test Mol Biomarkers* 2012;16(10):1241-5.